ライフサイエンスコーパス: darbepoetin alfa

1 p Therapy (TREAT) among patients assigned to darbepoetin alfa.

2 The risk of stroke was doubled with darbepoetin alfa.

3 Of the patients treated with darbepoetin alfa, 85% achieved 2 consecutive hemoglobin

4 hip among the initial hemoglobin response to darbepoetin alfa after two weight-based doses, the hemog

5 ere administered to 297 patients assigned to darbepoetin alfa and 496 patients assigned to placebo (P

6 stroke occurred in 101 patients assigned to darbepoetin alfa and 53 patients assigned to placebo (ha

7 r event occurred in 632 patients assigned to darbepoetin alfa and 602 patients assigned to placebo (h

8 disease occurred in 652 patients assigned to darbepoetin alfa and 618 patients assigned to placebo (h

9 oximately 20 pg/mL for EPOzeta, 30 pg/mL for darbepoetin alfa, and 80 pg/mL for C.E.R.A.

10 enous EPO and the recombinant forms EPOzeta, darbepoetin alfa, and C.E.R.A., from human urine is desc

11 Pegfilgrastim and darbepoetin alfa are effective and safe in facilitating

12 atients had a stroke, 101/2012 (5.0%) in the darbepoetin alfa arm and 53/2026 (2.6%) in the placebo a

13 Although darbepoetin alfa can effectively increase hemoglobin lev

14 is widely treated in the United States with darbepoetin alfa (DA) or epoetin alfa (EA).

15 Treatment with darbepoetin alfa did not improve clinical outcomes in pa

16 ssure, hemoglobin level, platelet count, and darbepoetin alfa dose did not differ between those with

17 level achieved after 4 weeks, the subsequent darbepoetin alfa dose, and outcomes in 1872 patients wit

18 Recombinant human erythropoietin (rhEPO) and darbepoetin alfa (DPO) are protein-based drugs for the t

19 were reported in 153 patients (13.5%) in the darbepoetin alfa group and 114 patients (10.0%) in the p

20 stroke occurred in 42 patients (3.7%) in the darbepoetin alfa group and 31 patients (2.7%) in the pla

21 urred in 576 of 1136 patients (50.7%) in the darbepoetin alfa group and 565 of 1142 patients (49.5%)

22 provement in patient-reported fatigue in the darbepoetin alfa group as compared with the placebo grou

23 %) in the placebo group (hazard ratio in the darbepoetin alfa group, 1.01; 95% confidence interval, 0

24 Patients who had a poor initial response to darbepoetin alfa had a lower average hemoglobin level at

25 disease and RED-HF (Reduction of Events with Darbepoetin alfa in Heart Failure) in heart failure pati

26 The use of darbepoetin alfa in patients with diabetes, chronic kidn

27 Our findings do not support the use of darbepoetin alfa in these patients.

28 The 2-fold increase in stroke with darbepoetin alfa in TREAT could not be attributed to any

29 parisons), despite receiving higher doses of darbepoetin alfa (median dose, 232 mug vs. 167 mug; P<0.

30 domized (double-blind) to placebo (N=157) or darbepoetin alfa (N=162) subcutaneously every 2 weeks fo

31 predictors of stroke included assignment to darbepoetin alfa (odds ratio 2.1; 95% confidence interva

32 We evaluated the effects of darbepoetin alfa on clinical outcomes in patients with s

33 All patients received darbepoetin alfa once every 3 weeks and were randomly as

34 ey disease, and anemia randomized to receive darbepoetin alfa or placebo.

35 In patients assigned to darbepoetin alfa, postrandomization systolic and diastol

36 rs could not be used to mitigate the risk of darbepoetin alfa-related stroke.

37 Darbepoetin alfa therapy was initiated in 92% of patient

38 nemia, we randomly assigned 2012 patients to darbepoetin alfa to achieve a hemoglobin level of approx

39 0 to 12.0 g per deciliter) to receive either darbepoetin alfa (to achieve a hemoglobin target of 13 g

40 use mortality or first HF hospitalization in darbepoetin alfa-treated patients compared with placebo

41 By intent-to-treat analysis, darbepoetin alfa treatment did not significantly improve

42 At week 27, darbepoetin alfa treatment increased median (interquarti

43 Darbepoetin alfa treatment was well tolerated and effect

44 tients assigned to placebo (hazard ratio for darbepoetin alfa vs. placebo, 1.05; 95% confidence inter

45 A poor initial hematopoietic response to darbepoetin alfa was associated with an increased subseq

46 The neutral effect of darbepoetin alfa was consistent across all prespecified

47 Darbepoetin alfa was initiated at 200 microg SQ every 2

48 th symptomatic HF and anemia, treatment with darbepoetin alfa was not associated with significant cli

49 esponsible for the increased risk related to darbepoetin alfa, we performed a nested case-control ana

50 er and 2026 patients to placebo, with rescue darbepoetin alfa when the hemoglobin level was less than

51 We defined a poor initial response to darbepoetin alfa (which occurred in 471 patients) as the